Amonafide
 | |
| Clinical data | |
|---|---|
| Trade names | Xanafide, Quinamed |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H17N3O3 |
| Molar mass | 283.325 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) is a drug that is being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.
It is being developed as an anti-cancer therapy by Antisoma.[1]
As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[2] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.
See also
References
- ↑ http://www.genengnews.com/news/bnitem.aspx?name=78979622
- ↑ http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"
External links
- Amonafide entry in the public domain NCI Dictionary of Cancer Terms
- Clinical trials of amonafide at ClinicalTrials.gov
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.